Host: Renée Simone Yolanda Allen, MD, MHSc., FACOG

Guest: Burton S. Brodsky, MD, FACOG

Low awareness of women’s risk factors and symptoms for ovarian cancer, compounded by common use of diagnostic laboratory tests that are less sensitive and not specifically approved for assessing the risk of malignant adnexal mass, are the most important reasons that the great majority of women with ovarian cancer are only diagnosed in late stage disease, when prognosis is far worse.

In this CME activity, join Dr. Burton Brodsky as he reviews best practices in malignancy risk assessment of adnexal mass to improve the detection of ovarian cancer in pre and postmenopausal women in earlier stages, ultimately enhancing their chances at surviving this devastating condition. Additionally, we will share practical strategies to best inform and empower patients, as well as practice management implications to facilitate patients and clinicians’ access to guideline recommended tools for ovarian cancer risk stratification.